{
    "clinical_study": {
        "@rank": "60208", 
        "arm_group": [
            {
                "arm_group_label": "Ondansetron, dexamethasone, aprepitant", 
                "arm_group_type": "Experimental", 
                "description": "Arm A: Ondansetron 0.15 mg/kg (max 16 mg) IV or PO every 8 hours for at least 3 days, but no longer than 5 days; dexamethasone 0.2mg/kg (max 10 mg) IV or PO daily for at least 3 days, but no longer than 5 days; and aprepitant 3 mg/kg (max 125 mg) PO on day 1, and aprepitant 2 mg/kg (max 80 mg) PO on days 2 and 3 during the first investigational antiemetic cycle. During the next investigational antiemetic cycle, members of this arm will be crossed-over into the placebo arm, where the aprepitant will be replaced by placebo and the dexamethasone dose will be increased to 0.4 mg/kg (max 20 mg) daily."
            }, 
            {
                "arm_group_label": "Ondansetron, Dexamethasone, placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Arm B: Ondansetron 0.15 mg/kg (max 16 mg) IV or PO every 8 hours for at least 3 days, but no more than 5 days; dexamethasone 0.4 mg/kg (max 20 mg) IV or PO daily for at least 3 days, but no more than 5 days; and a PO placebo for 3 days during the first investigational antiemetic cycle. During the second cycle, members this group will be crossed-over to the experimental arm, where the placebo will be replaced by aprepitant and the dexamethasone will be decreased by 50%."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to find out whether or not adding aprepitant(Emend\u00ae)  to the\n      standard therapy will help children who receive chemotherapy to have less nausea and\n      vomiting."
        }, 
        "brief_title": "Efficacy of Aprepitant (Emend\u00ae) in Children", 
        "condition": [
            "Nausea", 
            "Vomiting", 
            "Childhood Cancer"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Nausea", 
                "Vomiting"
            ]
        }, 
        "detailed_description": {
            "textblock": "1.1 Primary Aim To determine the efficacy of aprepitant (Emend\u00ae) in preventing and reducing\n      chemotherapy-induced nausea and vomiting (CINV) when added to standard antiemetic drug\n      regimens for children receiving highly emetogenic chemotherapy. The working hypothesis will\n      be that standard therapy + aprepitant is superior at preventing CINV than standard therapy +\n      placebo.\n\n      1.2 Secondary Aim To evaluate the safety and toxicity of aprepitant (Emend\u00ae) in children\n      receiving highly emetogenic chemotherapy when compared to standard antiemetic therapy +\n      placebo."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        under 20.99 years of age at enrollment\n\n        Scheduled to receive two identical cycles of highly emetogenic[1]  chemotherapy for\n        treatment of a primary malignancy, including:\n\n        Chemotherapy with any one or more of the following single agents in any combination:\n\n          -  Carboplatin\n\n          -  Carmustine >250 mg/m2\n\n          -  Cisplatin\n\n          -  Cyclophosphamide \u22651 g/m2\n\n          -  Dactinomycin\n\n        Or any of the following defined combinations:\n\n          -  Cyclophosphamide + anthracycline\n\n          -  Cyclophosphamide + etoposide\n\n          -  Cytarabine 150-200 mg/m2 + daunorubicin\n\n          -  Cytarabine 300 mg/m2 + etoposide\n\n          -  Cytarabine 300 mg/m2 + teniposide\n\n          -  Doxorubicin + ifosfamide\n\n          -  Doxorubicin + methotrexate 5 g/m2\n\n          -  Etoposide + ifosfamide\n\n        Exclusion Criteria:\n\n          -  Patients who have received aprepitant in the past.\n\n          -  Patients who demonstrate evidence of increased intracranial pressure."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "20 Years", 
            "minimum_age": "6 Months"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 18, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01661335", 
            "org_study_id": "0413"
        }, 
        "intervention": [
            {
                "arm_group_label": "Ondansetron, dexamethasone, aprepitant", 
                "description": "Ondansetron 0.15 mg/kg (max 16 mg) IV or PO every 8 hours for at least 3 days, but no longer than 5 days; dexamethasone 0.2mg/kg (max 10 mg) IV or PO daily for at least 3 days, but no longer than 5 days; and aprepitant 3 mg/kg (max 125 mg) PO on day 1, and aprepitant 2 mg/kg (max 80 mg) PO on days 2 and 3 during the first investigational antiemetic cycle. During the next investigational antiemetic cycle, members of this arm will be crossed-over into the placebo arm, where the aprepitant will be replaced by placebo and the dexamethasone dose will be increased to 0.4 mg/kg (max 20 mg) daily.", 
                "intervention_name": "Ondansetron, dexamethasone, aprepitant", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Aprepitant = Emend", 
                    "ARM A"
                ]
            }, 
            {
                "arm_group_label": "Ondansetron, Dexamethasone, placebo", 
                "description": "Ondansetron 0.15 mg/kg (max 16 mg) IV or PO every 8 hours  for at least 3 days, but no more than 5 days; dexamethasone 0.4 mg/kg (max 20 mg) IV or PO daily for at least 3 days, but no more than 5 days; and a PO placebo for 3 days during the first investigational antiemetic cycle.  During the second cycle, members this group will be crossed-over to the experimental arm, where the placebo will be replaced by aprepitant and the dexamethasone will be decreased by 50%.", 
                "intervention_name": "Ondansetron, Dexamethasone, placebo", 
                "intervention_type": "Drug", 
                "other_name": "ARM B"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Antiemetics", 
                "Dexamethasone", 
                "Ondansetron", 
                "Aprepitant", 
                "Dexamethasone acetate", 
                "Dexamethasone 21-phosphate", 
                "BB 1101"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Nausea", 
            "Vomiting", 
            "Children", 
            "Aprepitant", 
            "Emend\u00ae"
        ], 
        "lastchanged_date": "October 7, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Oklahoma City", 
                    "country": "United States", 
                    "state": "Oklahoma", 
                    "zip": "73104"
                }, 
                "name": "Jimmy Everest Center for Cancer and Blood Disorders in Children"
            }, 
            "investigator": [
                {
                    "last_name": "Rene McNall-Knapp, MD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Ashley Baker, MD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Efficacy of Aprepitant (Emend\u00ae) in Children Receiving Highly Emetogenic Chemotherapy", 
        "overall_contact": {
            "email": "rene-mcnall@ouhsc.edu", 
            "last_name": "Rene McNall-Knapp, MD", 
            "phone": "(405) 271-5311"
        }, 
        "overall_official": {
            "affiliation": "University of Oklahoma", 
            "last_name": "Rene McNall-Knapp, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "\u2022\tPercentage of study subjects who demonstrate a complete response, defined as no episodes of emesis and no use of rescue medications during the investigational antiemetic cycles.", 
                "measure": "Efficacy of aprepitant (Emend\u00ae) measured through a complete response", 
                "safety_issue": "No", 
                "time_frame": "Up to 11 weeks, or until 3 weeks after the second course of the study regimen"
            }, 
            {
                "description": "The total episodes of emesis within 7 days of the first chemotherapy administration of each cycle.\nThe total number of administrations of rescue medications given for breakthrough nausea or vomiting.", 
                "measure": "Efficacy of aprepitant (Emend\u00ae) measured through episodes of emesis and use of rescue medication.", 
                "safety_issue": "No", 
                "time_frame": "Up to 11 weeks, or until 3 weeks after the second course of the study regimen"
            }, 
            {
                "description": "\u2022 A modified, 5-day recall version of the Functional Living Index-Emesis (FLIE) questionnaire", 
                "measure": "Efficacy of aprepitant (Emend\u00ae) measured through impact of chemotherapy induced nausea and vomiting on daily life", 
                "safety_issue": "No", 
                "time_frame": "Up to 11 weeks, or until 3 weeks after the second course of the study regimen"
            }, 
            {
                "description": "\u2022 A modified version of the Baxter Animated Retching Faces (BARF) scale, administered daily.", 
                "measure": "Efficacy of aprepitant (Emend\u00ae) measured through a pictorial nausea scale", 
                "safety_issue": "No", 
                "time_frame": "Up to 11 weeks, or until 3 weeks after the second course of the study regimen"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01661335"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Occurrence of adverse events as per the NCI Common Terminology Criteria for Adverse Events (CTCAE) v.4.0. These will be reported spontaneously or on inquiry by the investigator/study nurse, and continuously monitored throughout the trial.\nWeekly complete blood count (CBC) for 3 weeks after each investigational antiemetic cycle.\nWeekly complete metabolic profile (CMP) for 3 weeks after each investigational antiemetic cycle.", 
            "measure": "Safety of aprepitant (Emend\u00ae)", 
            "safety_issue": "Yes", 
            "time_frame": "Up to 11 weeks, or until 3 weeks after the second course of the study regimen"
        }, 
        "source": "University of Oklahoma", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of Oklahoma", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}